|
RE: peptech Peptech, die Aktien werden knapp. Aufgrund der riesigen Nachfrage schiesst das Papier auf 0,72 EUro ( + 44 % )bzw. 1,23 AUD nach oben. Es wurde eine Partnerschaft mit der BASF Tochter Knoll geschlossen. PTD - ASX Company Announcement 15 November 2000 Part 1/1 -------- PEPTECH LIMITED --------------- HOMEX - Sydney ------------------------- Managing Directors Update -Human Therapeutics No 2 Yesterday, we announced that Peptech has signed a Letter Of Intent with Knoll AG, the pharmaceutical division of BASF Pharma. This is viewed as a very significant development in Peptech`s history on three fronts. Firstly, I consider it as a significant step towards executing a Licensing Agreement with Knoll. Secondly, for Knoll and it`s affiliates, it is viewed as a significant step because they would be licensed to manufacture and sell their D2E7 drug for the treat treatment of rheumatoid arthritis. Thirdly, Peptech would be able to receive significant rewards for the discovery of the TNF antibodies by way of front end payments and annual royalty income. Calculation of royalty income is to be based on the annual net sales generated by Knoll. good trades, SOM |
|
| aus der Diskussion: | Peptech : Ja ist den schon Weihnachten ? |
| Autor (Datum des Eintrages): | SOM.you. (15.11.00 10:37:38) |
| Beitrag: | 1 von 1 (ID:2352282) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |